Research projects (16)
Breast cancer patients face the risk of a contralateral breast cancer (CBC). Average lifetime risk is 15% but up to 60% for BRCA1/2 mutation carriers. Valid risk estimates are needed to develop a personalized prediction tool for CBC.
Risk prediction, screening and therapy of breast cancer in women from CHEK2 c.1100delC families in the Netherlands.
Circulating Biomarkers for Prostate Cancer
We aim to collect circulating markers in prostate cancer patients. Using circulating tumor derived DNA in plasma and circulating tumor cells we aim to improve the understanding of prostate cancer biology.
Using Whole Genome Sequencing data from metastatic prostate cancer lesions we seek to understand the drivers of metastatic prostate cancer biology.
Cyberknife Accelerated Partial Breast Irradiation
Improving the accuracy of the Cyberknife Accelerated Partial Breast Irradiation (CK-APBI) technique for postoperative radiotherapy for early-stage breast cancer
During this project we will implement therapeutic drug monitoring of oral targeted anti-cancer drugs to personalize the given treatment for each individual
Colorectal cancer patients often develop surgically removable liver metastases. We aim to develop a test to identify patients in need of additional treatment.
The objective of the MULTOMAB study is to set up a bank of prospectively collected blood samples for pharmacokinetic analyses of monoclonal antibodies
We are developing and evaluating an Online Value Clarification Tool (OnVaCT) to assist patients in clarifying their values around the decision to participate in early phase clinical trials (or not).
Response measurement study in prostate cancer patients, treated with radium-223, to improve response evaluation and understand the radium-223 induced immune response.
In this study, the prophylactic effect of scopolamine butyl is investigated on death rattle in a double blind placebo-controlled randomized study
Early progression detection in metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibitors by mutation dynamics in liquid biopsies.